Numinus Wellness Inc. (TSX-V:NUMI, OTC:LKYSF) has announced novel, proprietary methods - developed and validated in-house - for screening psychedelic mushroom compounds.
The testing will be available as part of its offerings for third-party clients and used for evidence-based conversations with the regulators, the company said in a statement.
"The testing we've developed and validated at Numinus Bioscience will facilitate the safety and efficacy testing of psychedelics for our products, our clients and strategic partners, and ultimately the industry," said the company's science officer and general manager, Sharan Sidhu in a statement.
"Working with regulators, we look forward to establishing tools to create a stronger foundation of analytical methods for psychedelic compounds and products," Sidhu added.
READ: Numinus Wellness receives conditional approval for listing on the Toronto Stock Exchange
Numinus Bioscience continues to develop analytical testing methods for the psychedelics industry.
“Among the matrices for which methodologies are being developed are Psilocybe mushroom fruiting bodies, extracts, and derivatives and, coupled with required testing such as contaminants and residues, the lab has validated methods for active constituents,” said the company.
“The Psilocybe mushrooms constituent screen include Psilocybin, Psilocin, Baeocystin, Norbaeocystin and Tryptophan, Norpsilocin and Aeruginascin which represent the most well-defined alkaloids for Psilocybe species,” it added.
Numinus has successfully developed a psychedelic mushroom toxicity screen that includes nephrotoxic and hepatotoxic compounds. The screen can quickly identify toxins from several varied species and is being offered to healthcare providers. Toxicity scans are completed using the Orbitrap, a state-of-the-art, industry-leading high-resolution mass spectrometry instrument.
"These in-house validated methods are another example of success in analytical development at Numimus, showing our commitment to strengthen regulatory confidence in these products," said Payton Nyquvest, CEO and founder of Numinus.
"We continue to push the boundaries as we establish our role as 'The Center of Excellence for Psychedelic Research and Development', with the furtherment of the industry at the heart of our advancements," added Nyquvest.
The research team at Numinus has characterized over 260 compounds, many for the first time in psychedelic mushrooms. The team continues to make novel discoveries in the research and development of Psilocybin. Numinus Bioscience also continues to build testing capabilities for Ketamine, LSD, Mescaline, DMT and MDMA.